Objective: To compare the effectiveness of cytology and co-testing for cervical cancer screening. Methods: Retrospective analysis for women who presented in colposcopy clinic of C.H.C.S.J. due to abnormal co-testing results during 2019 to 2022, a total of 2618 cases was included. All cases underwent co-testing and cervical biopsy (under colposcopy), with histologically confirmed outcome as the gold standard for efficacy comparison. Results: The detection rate of cytology and HPV-DNA for CIN2+ and cervical cancer were 7.5% (197/26 18) and 13.8% (360/2618), 0.76% (20/2618) and 0.92% (24/2618) respectively. Both screening method for the detection of CIN 2+ and cervical cancer are statistically significant (P<0.05). Co-testing has higher sensitivity (1.0) for diagnosed CIN 2+ and cervical cancer than cytology alone. Conclusion: Co-testing as cervical cancer screening is more sensitive to detect precancerous lesion and cervical cancer than cytology screening alone.